Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead clinical-stage candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.
Bolt is also advancing BDC-3042, a proprietary myeloid modulating agonist antibody targeting Dectin-2.
November 10, 2022
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateRead More
November 7, 2022
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual MeetingRead More
November 1, 2022
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare ConferenceRead More
November 16, 2022 at 1:15 PM EST
Stifel 2022 Healthcare Conference Read More
November 11, 2022
2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More
September 13, 2022 at 12:20 PM EDT
Morgan Stanley 20th Annual Global Healthcare Conference Read More